Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1934 - Analysis of EGFR mutation status in blood and CSF in lung adenocarcinoma patients with EGFR mutation and CNS metastasis by ddPCR (35P_PR)


18 Nov 2017


Poster lunch


Yang Sen


Annals of Oncology (2017) 28 (suppl_10): x186-x195. 10.1093/annonc/mdx729


Y. Sen, Q. Wang

Author affiliations

  • Internal Medicine-onclogy, The Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN


Abstract 1934


Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations benefit a great deal from EGFR tyrosine kinase inhibitors(TKIs). However, most patients recrudesce within one or two years, and many of them progress in the central nerve system (CNS). Owing to the blood–brain barrier, detecting tumor-derived cell-free DNA (cfDNA) in the blood of brain metastasis tumor patients is challenging. Detecting tumor-specific mutations in cerebral spinal fluid (CSF) may become an alternative method.


41 initial or progressed lung adenocarcinoma patients with EGFR mutation and CNS metastasis from Henan Cancer Hospital were included in this study. 41 patients were all detected EGFR mutation status in CSF with dropplet digital PCR (ddPCR) and 37 in 41 patients were detected EGFR mutation status in blood with the same method. Their clinical information were also collected at the same time.


The rate of EGFR mutations in blood (15/41, 36.6%) was obviously higher than that in CSF (24/37, 64.9%) (P = 0.013), especially in those with EGFR exon 19del mutation patients (13/16 vs 7/18, P = 0.017), without EGFR TKIs treated patients (8/11 vs 3/13, P = 0.038) and less than 60 years patients (17/22 vs 10/25, P = 0.010). In patients with CNS symptoms positive, the rate of EGFR mutations in CSF was higher than those negative (13/27 vs 2/14, P = 0.033). In patients with MRI indicating leptomeningeal metastasis, the rate of EGFR mutations in CSF was higher than those not indicating (8/11 vs 7/30, P = 0.003).


The EGFR mutation status in blood are different from that in CSF in patients with EGFR mutations and CNS metastasis. CNS symptoms and MRI indicating leptomeningeal metastasis are closely related with EGFR mutations status in CSF. Detecting EGFR mutation status in both extracranial and intracranial tumors will be helpful to make precise treatment, and detecting in blood and CSF with ddPCR may be an alternative.

Clinical trial identification

Legal entity responsible for the study

The Affiliated Cancer Hospital of Zhengzhou University




All authors have declared no conflicts of interest.

Table: 35P_PR

Characteristicn (%)
Male23 (56.1)
Female18 (43.9)
≥ 6016 (39)
< 6025 (61)
Smoking status
Yes12 (29.3)
No29 (70.7)
Brain metastases (MRI)
Only metastatic tumors30 (73.2)
With meningeal lesions11 (26.8)
Brain metastatic tumor number
Single10 (24.4)
Multiple31 (75.6)
Neurological symptoms
Positive15 (36.6)
Negative26 (63.4)
Prior TKIs treat
Yes28 (68.3)
No13 (31.7)
CSF EGFR mutation
197 (17.1)
216 (14.6)
Both2 (4.9)
Negative26 (63.4)
Blood EGFR mutation
1913 (31.7)
2110 (24.4)
Both1 (2.4)
Negative13 (31.7)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.